This new study estimates that the global GBM therapeutics market was valued at $370m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 2.4% to reach $449m by 2018. This low growth rate is primarily attributed to the patent expiry of Temodal/Temodar (temozolomide, TMZ) in Europe in 2009 and in the US in 2014. The entry of low cost generics in Europe in 2010 has led to a decrease in the market valuation. TMZ has been an established standard of care for newly diagnosed GBM patients since its approval in 2005 and has led to a considerable increase in the number of patients on chemotherapy. In addition, the late stage pipeline products including Avastin (bevacizumab), enzastaurin and cilengitide for GBM are not expected to significantly drive the market upon their launch as the clinical trial results have not shown a significant increase in survival rate.
Current Treatment Options are Moderately Successful in Meeting Market Demand
This research indicates that the current therapeutic options including TMZ, Gliadel (carmustine wafers), Avastin and nitrosoureas such as BCNU (carmustine), CeeNU (lomustine) and ACNU (nimustine) have been moderately successful in serving the market demand. TMZ has been established as standard of care for newly diagnosed GBM approved as an adjunct to surgery and has been successful in increasing survival time to 14 months. There is no established treatment guideline for treating recurrent GBM. GBM has a poor prognosis and a low survival rate despite current treatment options. Complete removal of the tumor is not possible as the tumor affects white matter tracts of the brain which cannot be treated with currently approved treatment options.
Late Stage Pipeline Candidates are Not Expected to Intensify Future Competition
The late stage products of the GBM therapeutics pipeline such as Avastin, trabedersen and enzastaurin are not expected to show significant impact on the GBM therapeutics market in the forecast period to 2018 due to dissatisfactory clinical results. Avastin has been approved as a single agent for recurrent GBM in the US by the Food and Drug Administration (FDA) and has also been rejected by the European Medicine Agency (EMA). Avastin is currently in the GBM pipeline for newly diagnosed GBM in combination with TMZ. In a Phase III study, enzastaurin has not show any statistical difference in the six month progression free survival in comparison to the approved drug CeeNU (lomustine).
Significant Unmet Need in the GBM Therapeutics Market
A significant level of unmet need is present in the GBM therapeutics market as the current treatment options have not been successful in satisfying physician and patient demand. Crossing the blood-brain barrier (BBB) is a significant challenge for drug development. The market is wide open for new entrants to fulfill the market’s unmet need. Current unmet need will continue through the forecast period as the GBM therapeutics market has a strong early stage pipeline which is not expected to be launched during the forecast period.
About this research:
This report is an essential source of information and analysis on the global GBM market. The report identifies the key trends shaping and driving the global GBM market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global GBM sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.